Patents by Inventor Mohamed Y. Ismail

Mohamed Y. Ismail has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170305840
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: December 9, 2016
    Publication date: October 26, 2017
    Inventors: Mark L. Nelson, Kwasi Ohemeng, Paul Abato, Victor Amoo, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Oak K. Kim, Jude Mathews, Rachid Mechiche
  • Patent number: 9365500
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: June 14, 2016
    Assignee: PARATEK PHARMACEUTICALS, INC.
    Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
  • Publication number: 20160039749
    Abstract: 11a,12-dehydrotetracycline compounds are described.
    Type: Application
    Filed: May 23, 2013
    Publication date: February 11, 2016
    Inventors: Joel Berniac, Mohamed Y. Ismail, Mark L. Nelson, Farzaneh Seyedi
  • Publication number: 20160031802
    Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: July 8, 2013
    Publication date: February 4, 2016
    Inventors: Upul Bandarage, Jackson Chen, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng
  • Publication number: 20150045329
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: May 19, 2014
    Publication date: February 12, 2015
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Kwasi Ohemeng, Paul Abato, Victor Amoo, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Oak K. Kim, Jude Mathews, Rachid Mechiche
  • Publication number: 20140309199
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
  • Publication number: 20140155357
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 5, 2014
    Inventors: Paul Abato, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng, Jingwen Pan
  • Patent number: 8481513
    Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: July 9, 2013
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Upul Bandarage, Jackson Chen, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng
  • Patent number: 8470804
    Abstract: 11a,12-dehydrotetracycline compounds are described.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: June 25, 2013
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Joel Berniac, Mohamed Y. Ismail, Mark L. Nelson, Faye Seyedi
  • Patent number: 8466132
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: June 18, 2013
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Paul Abato, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng, Jingwen Pan
  • Publication number: 20120283201
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: July 12, 2012
    Publication date: November 8, 2012
    Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhalie, Atul K. Verma, Laura Honeyman, Tadeusz Warchol, David Messersmith
  • Patent number: 8258120
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: September 4, 2012
    Assignees: Paratek Pharmaceuticals, Inc., Trustees of Tufts College
    Inventors: Mark L. Nelson, Mohamed Y. Ismail, Laura Honeyman
  • Publication number: 20120101070
    Abstract: 11a,12-dehydrotetracycline compounds are described.
    Type: Application
    Filed: December 29, 2011
    Publication date: April 26, 2012
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Joel Berniac, Mohamed Y. Ismail, Mark L. Nelson, Faye Seyedi
  • Patent number: 8119622
    Abstract: 7-phenyl-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. 7-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: February 21, 2012
    Assignee: Trustees of Tufts College
    Inventors: Mark L. Nelson, Mohamed Y. Ismail
  • Patent number: 8088755
    Abstract: 11a,12-dehydrotetracycline compounds are described.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: January 3, 2012
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Joel Berniac, Mohamed Y. Ismail, Mark L. Nelson, Faye Seyedi
  • Patent number: 8048867
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: November 1, 2011
    Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura McIntyre, Tadeusz Warchol, David Messersmith
  • Publication number: 20110092467
    Abstract: Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.
    Type: Application
    Filed: December 22, 2010
    Publication date: April 21, 2011
    Applicants: Paratek Pharmaceuticals, Inc., Trustees of Tufts College
    Inventors: Mark L. Nelson, Stuart B. Levy, Roger Frechette, Todd Bowser, Mohamed Y. Ismail
  • Publication number: 20110086822
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 14, 2011
    Inventors: Mark L. Nelson, Kwasi Ohemeng, Roger Frechette, Paul Abato, Victor Amoo, Upul Bandarage, Joel Berniac, Beena Bhatia, Jackson Chen, Mohamed Y. Ismail, Oak Kim, Laura Honeyman, Rachid Mechiche, Andre Pearson, Laxma Reddy Nagavelli, Paul Sheahan, Atul K. Verma, Peter Viski, Tadeusz Warchol
  • Patent number: 7858600
    Abstract: Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: December 28, 2010
    Assignees: Paratek Pharmaceuticals, Inc., Trustees of Tufts College
    Inventors: Mark L. Nelson, Stuart B. Levy, Roger Frechette, Todd Bowser, Mohamed Y. Ismail
  • Publication number: 20100305072
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
    Type: Application
    Filed: December 21, 2007
    Publication date: December 2, 2010
    Inventors: Oak K. Kim, Mark L. Nelson, Paul Abato, Haregewein Assefa, Joel Bernaiac, Mohamed Y. Ismail, Todd Bowser, Mark Grier, Beena Bhatia, Atul K. Verma, Laura Honeyman, Jingwen Pan